BamSEC and AlphaSense Join Forces
Learn More

ARS Pharmaceuticals Inc. – Material Contracts

NASDAQ: SPRY    
Share price (8/6/26): $5.55    
Market cap (8/6/26): $551 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 3 pages First Amendment to Commercial Supply Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Second Amendment to Co-Promotion Agreement
12/34/56
EX-10.1
from 8-K 10 pages ARS Pharmaceuticals, Inc. Executive Employment Agreement for Donn Casale
12/34/56
EX-10.2
from 10-Q 3 pages First Amendment to Co-Promotion Agreement
12/34/56
EX-10.3
from 10-Q 3 pages Third Amendment to Manufacturing Agreement
12/34/56
EX-10.1
from 10-Q 47 pages Co-Promotion Agreement
12/34/56
EX-10.1
from 10-Q 3 pages ARS Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Amended Effective: April 1, 2025
12/34/56
EX-10.30
from 10-K 3 pages Renaissance December 6, 2024 Confidential by E-Mail Attn: Brian Dorsey ARS Pharmaceuticals Operations, Inc. 11682 El Camino Real, Suite 120 San Diego, Ca 92130 [***]
12/34/56
EX-10.29
from 10-K 13 pages ARS Supply Agreement
12/34/56
EX-10.28
from 10-K 25 pages Commercial Supply Agreement
12/34/56
EX-10.27
from 10-K 74 pages Collaboration, License and Distribution Agreement
12/34/56
EX-10.1
from 10-Q 8 pages Second Amendment to Manufacturing Agreement
12/34/56
EX-10.1
from 10-Q 3 pages ARS Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Amended Effective: June 28, 2024
12/34/56
EX-10.9
from 10-K 3 pages ARS Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Amended Effective: December 6, 2022
12/34/56
EX-10.1
from 10-Q 4 pages First Amendment to Manufacturing Agreement
12/34/56
EX-10
from 10-K 11 pages ARS Pharmaceuticals, Inc. Executive Employment Agreement for Alexander A. Fitzpatrick
12/34/56
EX-10
from 10-K 7 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (I) Not Material and (II) Is the Type That the Registrant Treats as Private and Confidential. Termination Agreement
12/34/56
EX-10
from 10-K 33 pages ARS Pharmaceuticals, Inc. Change in Control and Severance Benefit Plan Approved by the Board of Directors: November 6, 2020
12/34/56
EX-10.1
from 8-K 9 pages ARS Pharmaceuticals, Inc. Executive Employment Agreement for Brian T. Dorsey
12/34/56
EX-10.13
from 8-K 6 pages Master Services Agreement
12/34/56